Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

New York, New York 10021


RATIONALE: Thalidomide may stop the growth of neuroendocrine tumors by stopping blood flow to the tumor. PURPOSE: Phase II trial to study the effectiveness of thalidomide in treating patients who have metastatic neuroendocrine tumors.

Study summary:

OBJECTIVES: - Determine the safety and efficacy of thalidomide in patients with metastatic low-grade neuroendocrine tumors. OUTLINE: Patients receive oral thalidomide once daily on weeks 1-8. Courses repeat every 8 weeks in the absence of disease progression or unacceptable toxicity. PROJECTED ACCRUAL: A total of 14-25 patients will be accrued for this study.


DISEASE CHARACTERISTICS: - Histologically confirmed low-grade neuroendocrine tumors - Carcinoid tumors - Islet cell tumors - Metastatic disease - Progression of disease within past 4 weeks by radiological evidence - At least 1 bidimensionally measurable lesion by CT scan or MRI - Bone metastasis not considered measurable if only site of disease - No active brain metastases PATIENT CHARACTERISTICS: Age: - Not specified Performance status: - Karnofsky 70-100% Life expectancy: - More than 3 months Hematopoietic: - WBC at least 3,000/mm^3 - Absolute neutrophil count at least 1,500/mm^3 - Platelet count at least 100,000/mm^3 Hepatic: - Bilirubin normal - AST no greater than 2.5 times upper limit of normal (ULN) Renal: - Creatinine no greater than 1.5 times ULN OR - Creatinine clearance at least 50 mL/min Other: - Not pregnant or nursing - Negative pregnancy test - Fertile patients must use 2 forms of effective contraception for 4 weeks before, during, and for 4 weeks after study - No grade 2 or greater neuropathy - No other clinical circumstances that would preclude study - No other prior malignancy except: - Non-melanoma skin cancer - Other cancer that has been curatively treated, has had no evidence of recurrence within the past 5 years, and is at low risk for recurrence PRIOR CONCURRENT THERAPY: Biologic therapy: - No prior thalidomide - No concurrent interferon Chemotherapy: - No concurrent chemotherapy Endocrine therapy: - Not specified Radiotherapy: - At least 4 weeks since prior radiotherapy - No concurrent radiotherapy Surgery: - At least 4 weeks since prior major surgery Other: - No more than 1 prior systemic therapy regimen - At least 4 weeks since prior systemic therapy regimen - No other concurrent therapeutic agent



Primary Contact:

Study Chair
Leonard B. Saltz, MD
Memorial Sloan-Kettering Cancer Center

Backup Contact:


Location Contact:

New York, New York 10021
United States

There is no listed contact information for this specific location.

Site Status: N/A

Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.

Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.